Candidate targets of copy number deletion events across 17 cancer types.
biomarker discovery
cancer genomics
copy number aberration (CNA)
meta-analysis in cancer
mutational signature
somatic variation
Journal
Frontiers in genetics
ISSN: 1664-8021
Titre abrégé: Front Genet
Pays: Switzerland
ID NLM: 101560621
Informations de publication
Date de publication:
2022
2022
Historique:
received:
12
08
2022
accepted:
28
12
2022
entrez:
2
2
2023
pubmed:
3
2
2023
medline:
3
2
2023
Statut:
epublish
Résumé
Genome variation is the direct cause of cancer and driver of its clonal evolution. While the impact of many point mutations can be evaluated through their modification of individual genomic elements, even a single copy number aberration (CNA) may encompass hundreds of genes and therefore pose challenges to untangle potentially complex functional effects. However, consistent, recurring and disease-specific patterns in the genome-wide CNA landscape imply that particular CNA may promote cancer-type-specific characteristics. Discerning essential cancer-promoting alterations from the inherent co-dependency in CNA would improve the understanding of mechanisms of CNA and provide new insights into cancer biology and potential therapeutic targets. Here we implement a model using segmental breakpoints to discover non-random gene coverage by copy number deletion (CND). With a diverse set of cancer types from multiple resources, this model identified common and cancer-type-specific oncogenes and tumor suppressor genes as well as cancer-promoting functional pathways. Confirmed by differential expression analysis of data from corresponding cancer types, the results show that for most cancer types, despite dissimilarity of their CND landscapes, similar canonical pathways are affected. In 25 analyses of 17 cancer types, we have identified 19 to 169 significant genes by copy deletion, including RB1, PTEN and CDKN2A as the most significantly deleted genes among all cancer types. We have also shown a shared dependence on core pathways for cancer progression in different cancers as well as cancer type separation by genome-wide significance scores. While this work provides a reference for gene specific significance in many cancers, it chiefly contributes a general framework to derive genome-wide significance and molecular insights in CND profiles with a potential for the analysis of rare cancer types as well as non-coding regions.
Identifiants
pubmed: 36726722
doi: 10.3389/fgene.2022.1017657
pii: 1017657
pmc: PMC9885371
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1017657Informations de copyright
Copyright © 2023 Huang and Baudis.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Genomics. 2020 Sep;112(5):3331-3341
pubmed: 32413400
Annu Rev Pathol. 2009;4:127-50
pubmed: 18767981
Genes Dev. 2008 Jun 1;22(11):1439-44
pubmed: 18519636
Tumour Biol. 2007;28(5):290-300
pubmed: 17962726
J Clin Oncol. 1999 Jan;17(1):380-93
pubmed: 10458257
BMC Genomics. 2014 Jan 29;15:82
pubmed: 24476156
Nature. 2020 Nov;587(7832):126-132
pubmed: 32879494
J Toxicol Environ Health B Crit Rev. 2009;12(5-6):307-33
pubmed: 20183525
Clin Cancer Res. 2018 Aug 1;24(15):3717-3728
pubmed: 29666300
BMC Cancer. 2007 Dec 18;7:226
pubmed: 18088415
Nature. 2020 Feb;578(7793):122-128
pubmed: 32025013
Genome Biol. 2011;12(4):R41
pubmed: 21527027
Mech Ageing Dev. 2008 Jul-Aug;129(7-8):391-407
pubmed: 18406444
Nat Rev Cancer. 2018 Nov;18(11):696-705
pubmed: 30293088
Nat Rev Cancer. 2003 Feb;3(2):130-8
pubmed: 12563312
Nucleic Acids Res. 2015 Jan;43(Database issue):D825-30
pubmed: 25428357
Nat Genet. 2020 Feb;52(2):208-218
pubmed: 32015527
Med Res Rev. 2014 Mar;34(2):280-300
pubmed: 23696246
Nat Biotechnol. 2022 Jun;40(6):817-820
pubmed: 35705716
Front Endocrinol (Lausanne). 2018 Jul 24;9:405
pubmed: 30087655
Science. 2013 Mar 29;339(6127):1546-58
pubmed: 23539594
PLoS One. 2012;7(8):e43689
pubmed: 22937079
Nature. 2007 Apr 12;446(7137):758-64
pubmed: 17344859
Cell Genom. 2021 Nov 10;1(2):
pubmed: 35311178
Nat Genet. 2013 Oct;45(10):1127-33
pubmed: 24071851
Nat Genet. 2020 Mar;52(3):331-341
pubmed: 32025003
Oncogene. 2013 Apr 18;32(16):2037-47
pubmed: 22751117
Front Genet. 2020 Feb 26;11:160
pubmed: 32174978
Nucleic Acids Res. 2011 Jan;39(Database issue):D945-50
pubmed: 20952405
Cell. 2008 May 2;133(3):403-14
pubmed: 18455982
Cell. 2011 Jan 7;144(1):27-40
pubmed: 21215367
Science. 1996 Jan 19;271(5247):350-3
pubmed: 8553070
Nature. 2010 Feb 18;463(7283):899-905
pubmed: 20164920
Nature. 2012 Sep 6;489(7414):57-74
pubmed: 22955616
N Engl J Med. 2015 Nov 12;373(20):1926-36
pubmed: 26559571
Nucleic Acids Res. 2021 Jan 8;49(D1):D545-D551
pubmed: 33125081
Cancer Discov. 2012 May;2(5):401-4
pubmed: 22588877
BMC Med Genet. 2019 Nov 9;20(1):175
pubmed: 31706287
Bioinformatics. 2010 Jan 1;26(1):139-40
pubmed: 19910308
Cancer Lett. 2006 Jan 28;232(1):48-57
pubmed: 16221525
Mol Med. 1997 Jan;3(1):5-20
pubmed: 9132280
Cell. 2018 Aug 9;174(4):1034-1035
pubmed: 30096302
Cell. 1991 Jan 25;64(2):313-26
pubmed: 1988150
Mutat Res Rev Mutat Res. 2018 Jul - Sep;777:29-51
pubmed: 30115429
CA Cancer J Clin. 1994 May-Jun;44(3):160-70
pubmed: 7621068
Nature. 2017 Mar 2;543(7643):122-125
pubmed: 28178237
Database (Oxford). 2021 Jul 17;2021:
pubmed: 34272855
Nat Genet. 2018 May;50(5):708-717
pubmed: 29686388
Nat Genet. 2013 Oct;45(10):1113-20
pubmed: 24071849
Eur J Cancer. 2005 Nov;41(16):2462-78
pubmed: 16213704
Nat Rev Genet. 2009 Aug;10(8):551-64
pubmed: 19597530
Proc Natl Acad Sci U S A. 2014 Jul 29;111(30):11139-44
pubmed: 25024180
Annu Rev Med. 1999;50:401-23
pubmed: 10073286
Hum Mutat. 2022 Jun;43(6):791-799
pubmed: 35297548
EMBO J. 1997 Sep 1;16(17):5353-62
pubmed: 9311995